drugset / Trial / NCT02389543
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, randomized clinical study with two stages to assess the maximum tolerated dose (MTD), efficacy, and safety of selinexor, lenalidomide, and dexamethasone (SLd) in patients with relapsed/refractory (RR) multiple myeloma (MM). The stages are dose escalation (Phase 1) and expansion (Phase 2).
Timeline
- Start
- 2015-07
- Primary completion
- 2018-01
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Selinexor | Other / unclassified | 60 mg | — |
| Subject | Selinexor | Other / unclassified | 80 mg | — |
| Subject | Selinexor | Other / unclassified | 100 mg | — |